Phyllis A Gimotty - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Phyllis A Gimotty

Showing results (41-50 of 148) with videos related to

Pageof 15

Sort By:

Nature Medicine|December 25, 2007

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapyRonald J Buckanovich, Andrea Facciabene, Sarah Kim, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015

DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous LeukemiaAlison R Sehgal, Phyllis A Gimotty, Jianhua Zhao, et al.

The Laryngoscope|June 1, 2017

Barriers to generating PDX models of HPV-related head and neck cancerNicole D Facompre, Varun Sahu, Kathleen T Montone, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2007

Tumor vascular proteins as biomarkers in ovarian cancerRonald J Buckanovich, Dimitra Sasaroli, Anne O'Brien-Jenkins, et al.

Human Pathology|April 10, 2019

Stromal inflammatory cells are associated with poorer prognosis in primary cutaneous melanomaSook Jung Yun, Shujing Liu, Meghan Buckley, et al.

Blood Advances|February 2, 2019

Gene-based FVIIa prophylaxis modulates the spontaneous bleeding phenotype of hemophilia A ratsShannon M Zintner, Juliana C Small, Giulia Pavani, et al.

Cancer Biology & Therapy|April 22, 2006

Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironmentRonald J Buckanovich, Dimitra Sasaroli, Ann O'brien-Jenkins, et al.

Neoplasia (New York, N.Y.)|December 11, 2012

Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularizationSelene Nunez-Cruz, Phyllis A Gimotty, Matthew W Guerra, et al.

Cancer|May 28, 2009

Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancerSarah F Adams, Douglas A Levine, Mark G Cadungog, et al.

The Journal of Molecular Diagnostics : JMD|August 11, 2007

Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanomaCynthia Spittle, M Renee Ward, Katherine L Nathanson, et al.

Pageof 15

Search research articles

Showing results (41-50 of 148) with videos related to

Sort By:

Pageof 15

Nature Medicine|December 25, 2007

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapyRonald J Buckanovich, Andrea Facciabene, Sarah Kim, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015

DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous LeukemiaAlison R Sehgal, Phyllis A Gimotty, Jianhua Zhao, et al.

The Laryngoscope|June 1, 2017

Barriers to generating PDX models of HPV-related head and neck cancerNicole D Facompre, Varun Sahu, Kathleen T Montone, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2007

Tumor vascular proteins as biomarkers in ovarian cancerRonald J Buckanovich, Dimitra Sasaroli, Anne O'Brien-Jenkins, et al.

Human Pathology|April 10, 2019

Stromal inflammatory cells are associated with poorer prognosis in primary cutaneous melanomaSook Jung Yun, Shujing Liu, Meghan Buckley, et al.

Blood Advances|February 2, 2019

Gene-based FVIIa prophylaxis modulates the spontaneous bleeding phenotype of hemophilia A ratsShannon M Zintner, Juliana C Small, Giulia Pavani, et al.

Cancer Biology & Therapy|April 22, 2006

Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironmentRonald J Buckanovich, Dimitra Sasaroli, Ann O'brien-Jenkins, et al.

Neoplasia (New York, N.Y.)|December 11, 2012

Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularizationSelene Nunez-Cruz, Phyllis A Gimotty, Matthew W Guerra, et al.

Cancer|May 28, 2009

Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancerSarah F Adams, Douglas A Levine, Mark G Cadungog, et al.

The Journal of Molecular Diagnostics : JMD|August 11, 2007

Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanomaCynthia Spittle, M Renee Ward, Katherine L Nathanson, et al.

Pageof 15